Veterans Medical Marijuana Access: Federal Restrictions and State Programs

Executive Summary

Veterans seeking medical marijuana face a unique paradox: while millions of Americans can access cannabis legally at the state level, federal law prohibits Department of Veterans Affairs physicians from recommending it, forcing veterans to navigate a fragmented system of state programs, private doctors, and out-of-pocket costs. As of September 2026, approximately 9 million veterans live in states with medical marijuana programs, yet VA healthcare providers cannot certify them for participation due to cannabis's Schedule I status under the Controlled Substances Act. Recent legislative efforts in Massachusetts and at the federal level aim to expand veterans' access through alternative certification pathways, reduced fees, and dedicated research programs. The issue intersects healthcare policy, federal-state conflicts, military culture, and the treatment of conditions disproportionately affecting veterans including post-traumatic stress disorder, chronic pain, and traumatic brain injury. With veterans representing roughly 7% of the U.S. adult population but accounting for higher rates of opioid prescriptions and suicide, access to medical marijuana has emerged as both a clinical question and a policy priority across the political spectrum.

Why Veterans Medical Marijuana Access Matters

More than 2 million veterans currently use cannabis for medical purposes, according to survey data, yet most do so without formal state program enrollment or clinical guidance from their VA providers. The stakes extend beyond individual patient choice to encompass public health outcomes, healthcare system costs, and the federal government's obligations to those who served. Veterans experience post-traumatic stress disorder at rates 3-4 times higher than the general population, with the VA estimating that 11-20% of veterans who served in Operations Iraqi Freedom and Enduring Freedom have PTSD in a given year. Chronic pain affects approximately 50% of veterans seeking VA care, compared to 30% of non-veterans. Traumatic brain injury, often called the "signature wound" of recent conflicts, affects an estimated 400,000 service members from the post-9/11 era. For these conditions, standard pharmaceutical treatments frequently involve opioids, benzodiazepines, and antipsychotics—medications with significant side effect profiles and addiction risks. The opioid epidemic has hit the veteran community particularly hard. Veterans are twice as likely to die from accidental opioid overdoses compared to non-veterans, according to data from the Centers for Disease Control and Prevention. In 2019, the VA issued more than 13 million opioid prescriptions. Research published in the Journal of the American Medical Association found that states with medical marijuana programs saw a 24.8% reduction in opioid overdose deaths, suggesting cannabis access could serve as a harm reduction strategy. Financially, the issue affects both individual veterans and the VA healthcare system. Veterans without VA physician certification must pay out-of-pocket for private doctor visits (typically $100-300) and state medical marijuana card fees ($50-200 annually). The VA spent approximately $90 billion on healthcare in fiscal year 2025, with pain management and mental health services representing major cost centers. If medical marijuana proves effective for even a subset of veterans currently on pharmaceutical regimens, the cost implications could be substantial. The veteran advocacy community has mobilized around this issue with unusual bipartisan support. Organizations including the American Legion, Veterans of Foreign Wars, Iraq and Afghanistan Veterans of America, and Disabled American Veterans have all endorsed expanded research and access. The American Legion's 2017 resolution calling for cannabis rescheduling marked a significant shift in mainstream veteran organization positions.

Background and History: From Prohibition to State-Federal Conflict

The modern conflict over veterans' medical marijuana access began in 1996 when California became the first state to legalize medical cannabis, creating an immediate tension with federal law and VA policy that persists three decades later.

1970: The Controlled Substances Act Foundation

The Controlled Substances Act, enacted as Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970, established the federal drug scheduling system. Cannabis was placed in Schedule I, defined as substances with "no currently accepted medical use and a high potential for abuse" under 21 U.S.C. § 812. This classification, intended as temporary pending a commission review, became permanent despite the 1972 Shafer Commission recommendation to decriminalize personal cannabis use. Schedule I status prohibits federal physicians from prescribing or recommending cannabis, forming the legal foundation for current VA restrictions.

1996-2010: State Medical Marijuana Programs Emerge

California's Proposition 215, the Compassionate Use Act of 1996, created the first state-level medical marijuana program. By 2010, fourteen states had enacted medical cannabis laws. Veterans in these states faced immediate barriers: while state law permitted medical use with physician certification, VA doctors operated under federal law and VA policy directive 2011-004, which explicitly prohibited VA providers from completing state medical marijuana forms or recommending cannabis in any capacity. The policy created a two-tier system. Veterans with private insurance or resources could see non-VA physicians for certification, while veterans relying exclusively on VA healthcare had no pathway to legal state program participation. The VA's position was that federal employees could not recommend a Schedule I substance without violating the Controlled Substances Act and potentially facing criminal liability under 21 U.S.C. § 841.

2014-2016: Congressional Amendments and Policy Clarification

The 2014 Consolidated Appropriations Act included language prohibiting the Department of Justice from using funds to prevent states from implementing medical marijuana laws. While this protected state programs from federal interference, it did not address VA physician restrictions. In January 2016, Representative Earl Blumenauer introduced the Veterans Equal Access amendment, which would have allowed VA physicians to provide medical marijuana recommendations in states with legal programs. The amendment passed the House Veterans' Affairs Committee but was stripped from the final Military Construction and Veterans Affairs appropriations bill. In July 2016, the VA issued a directive clarifying that veterans would not be denied VA services solely for participating in state medical marijuana programs. This represented progress but did not authorize VA physicians to provide recommendations. Veterans could discuss cannabis use with VA doctors without penalty, but those doctors still could not certify them for state programs.

2017-2021: Research Authorization and Continued Advocacy

The VA Medicinal Cannabis Research Act of 2018, introduced by Representative Lou Correa, proposed the first federally funded clinical trials of cannabis for veteran-specific conditions. The bill stalled in committee, but it signaled growing congressional interest in evidence-based policy. In 2020, the House of Representatives passed the Veterans Medical Marijuana Safe Harbor Act as part of a broader appropriations package. The provision would have protected veterans and VA employees from federal prosecution for participating in state cannabis programs. The Senate removed the language before final passage. The 2021 infrastructure bill included a provision requiring the VA to survey veterans about cannabis use patterns and perceived benefits. The resulting 2022 VA survey found that 34% of veterans in medical marijuana states had used cannabis for health purposes in the past year, with 78% reporting symptom improvement.

2022-2024: State-Level Innovations

Facing federal inaction, several states created veteran-specific accommodations within their medical marijuana programs. New York eliminated application fees for veterans in 2022. Illinois added PTSD as a qualifying condition specifically in response to veteran advocacy. Oklahoma's constitutional amendment establishing medical marijuana included language prioritizing veteran access. New Mexico went further in 2023, creating an alternative certification pathway allowing veterans to self-certify for PTSD-related medical marijuana cards with proof of VA healthcare enrollment and a PTSD diagnosis code from VA medical records. This model avoided requiring a physician recommendation while still linking access to documented medical need.

2025-2026: Federal Rescheduling and Massachusetts Innovation

In August 2025, the Drug Enforcement Administration published a Notice of Proposed Rulemaking to reschedule cannabis from Schedule I to Schedule III under 21 U.S.C. § 811. The proposed rule followed a Department of Health and Human Services recommendation based on an FDA scientific review. Schedule III status would acknowledge accepted medical use but would not automatically authorize VA physicians to recommend cannabis, as VA policy and medical practice standards would require separate revision. In September 2026, Massachusetts Governor Maura Healey filed legislation allowing veterans to obtain medical marijuana cards without a physician recommendation, instead using DD-214 discharge papers and self-attestation of a qualifying condition. The Massachusetts proposal built on the New Mexico model but eliminated the requirement for VA medical records, recognizing that many veterans receive care outside the VA system. The bill proposed waiving the state's $50 biennial registration fee for veterans and creating a veteran-specific education program on cannabis use, drug interactions, and impairment.

Key Players in the Veterans Medical Marijuana Debate

Department of Veterans Affairs

The VA operates the largest integrated healthcare system in the United States, serving 9 million enrolled veterans through 1,298 healthcare facilities. The VA's position on medical marijuana has evolved from outright prohibition of discussion to tolerance of patient use, but the agency maintains that federal law prevents VA physicians from recommending cannabis. VA Secretary Denis McDonough testified before Congress in 2024 that the agency supports further research but cannot change physician recommendation policies without congressional action or cannabis rescheduling. The VA's Office of Research and Development has funded preliminary studies on cannabinoid mechanisms but no large-scale clinical trials of whole-plant cannabis for veteran populations.

Drug Enforcement Administration

The DEA maintains regulatory authority over controlled substances under 21 U.S.C. § 871. The agency's 2025 proposed rescheduling of cannabis to Schedule III represents the most significant policy shift in five decades, though the final rule remains under review as of September 2026. DEA Administrator Anne Milgram has stated that rescheduling decisions are based on scientific and medical evaluations from HHS, not political considerations. The DEA's historical position has been that international treaty obligations under the 1961 Single Convention on Narcotic Drugs constrain U.S. cannabis policy, though legal scholars dispute whether medical use violates treaty terms.

American Legion

With 1.6 million members, the American Legion represents the largest wartime veterans service organization. In 2016, the organization passed Resolution 11, calling for cannabis rescheduling and expanded research. The Legion's position emphasizes veteran choice and evidence-based medicine rather than endorsing cannabis as a treatment. National Commander Daniel Seehafer testified before the House Veterans' Affairs Committee in 2023 that the organization receives more member inquiries about medical marijuana access than any other healthcare topic.

Veterans of Foreign Wars

The VFW, with 1.4 million members, adopted a resolution in 2019 supporting federal legislation to allow VA physicians to recommend medical marijuana in compliance with state law. The organization's advocacy focuses on the physician-patient relationship and the principle that veterans should have the same healthcare options as non-veterans. The VFW has not taken a position on cannabis legalization more broadly, limiting its advocacy to medical access for veterans with qualifying conditions.

Iraq and Afghanistan Veterans of America

IAVA, representing post-9/11 veterans, has prioritized medical marijuana access as part of its mental health and suicide prevention platform. The organization's 2025 member survey found that 62% of respondents supported allowing VA doctors to recommend medical marijuana, with support crossing party lines. IAVA's advocacy emphasizes opioid alternatives and the specific needs of veterans with combat-related PTSD and traumatic brain injury.

National Organization for the Reform of Marijuana Laws

NORML has worked with veteran organizations since 2014 to advance access legislation. The organization provides legal support for veterans facing federal employment consequences for state-legal medical marijuana use and maintains a veteran-specific legal defense fund. NORML's position extends beyond medical access to full legalization, but the organization has supported incremental veteran-focused reforms as interim measures.

Smart Approaches to Marijuana

SAM, founded in 2013, opposes cannabis legalization and has raised concerns about veteran-specific medical marijuana policies. The organization argues that insufficient evidence supports cannabis efficacy for PTSD and that alternative treatments should be prioritized. SAM has pointed to studies showing associations between cannabis use and psychotic symptoms in vulnerable populations, arguing that veterans with mental health conditions face particular risks. The organization supports FDA-approved cannabinoid medications like dronabinol but opposes whole-plant cannabis access outside formal drug approval processes.

Legal and Regulatory Framework

Veterans' medical marijuana access exists in a complex legal space where federal prohibition, state medical programs, VA policy directives, and professional medical standards intersect and often conflict. The Controlled Substances Act remains the foundational federal law. Section 812 establishes five schedules of controlled substances, with Schedule I reserved for drugs with no accepted medical use. Cannabis's Schedule I status means that under 21 U.S.C. § 841, manufacturing, distributing, or dispensing cannabis is a federal crime punishable by up to five years imprisonment for a first offense. While the Rohrabacher-Farr amendment (now the Joyce-Leahy amendment) prohibits the Department of Justice from using funds to prevent states from implementing medical marijuana laws, this protection does not extend to federal employees recommending cannabis. VA physicians are federal employees subject to federal law and VA policy. VA Directive 1315 governs clinical programs and practices, while VHA Directive 1004.01 specifically addresses medical marijuana. The current directive, updated in 2017, states that VA providers "will not complete forms or take other actions to assist Veterans to participate in state-approved marijuana programs." The directive does allow providers to discuss marijuana use with patients, record use in medical records, and adjust treatment plans accordingly, but stops short of permitting recommendations or certifications. The distinction between "recommendation" and "prescription" carries legal significance. Under the Controlled Substances Act, Schedule I substances cannot be prescribed. State medical marijuana laws typically require physician "recommendations" or "certifications" rather than prescriptions, creating a semantic workaround. However, federal courts have held that even recommendations constitute sufficient involvement to implicate federal law. In Conant v. Walters, 309 F.3d 629 (9th Cir. 2002), the Ninth Circuit ruled that the First Amendment protects physician-patient discussions about medical marijuana, but the case did not address whether federal employees could provide recommendations. The Administrative Procedure Act, 5 U.S.C. § 551 et seq., governs how federal agencies like the DEA can change drug scheduling. The DEA's proposed rescheduling of cannabis to Schedule III follows the APA's notice-and-comment process. If finalized, Schedule III status would acknowledge accepted medical use but would subject cannabis to FDA regulation as a prescription drug. This would not automatically authorize VA physicians to recommend cannabis, as the VA would need to issue new policy directives and establish clinical practice guidelines. State medical marijuana laws vary significantly in structure. As of September 2026, 38 states and the District of Columbia have comprehensive medical marijuana programs, while 24 states have legalized adult-use cannabis. Qualifying conditions range from specific diagnoses like cancer and epilepsy to broader categories like chronic pain. Most states require physician certification, though the specific requirements vary. Some states accept out-of-state medical marijuana cards through reciprocity agreements, while others require state residency and in-state physician certification. PTSD qualification presents particular complexity for veterans. While 37 medical marijuana states list PTSD as a qualifying condition, definitions vary. Some states require formal diagnosis by a psychiatrist or psychologist, while others accept primary care physician assessment. The VA uses specific diagnostic criteria from the DSM-5, but state programs may use different standards. This creates situations where a veteran has a PTSD diagnosis in VA records but cannot easily translate that into state program eligibility without a separate evaluation. Federal employment and benefits consequences add another legal layer. Veterans who use medical marijuana in compliance with state law do not lose VA healthcare eligibility or benefits under current VA policy. However, veterans seeking federal employment face complications, as most federal agencies maintain drug-free workplace policies that prohibit cannabis use regardless of state law. Veterans receiving disability compensation are not penalized for medical marijuana use, but those seeking increases in disability ratings may find that cannabis use complicates psychiatric evaluations. The Gun Control Act of 1968, specifically 18 U.S.C. § 922(g)(3), prohibits firearm possession by "unlawful users" of controlled substances. The Bureau of Alcohol, Tobacco, Firearms and Explosives has issued guidance stating that medical marijuana cardholders are prohibited persons under federal law. This creates a significant barrier for veterans, many of whom own firearms. Several federal court challenges to this policy are pending as of September 2026.

State-by-State Breakdown of Veterans Medical Marijuana Access

State medical marijuana programs vary dramatically in their accommodation of veterans, from fee waivers and alternative certification pathways to no special provisions at all.

State	Program Status	PTSD Qualifying	Veteran Benefits	Key Dates
California	Medical + Adult Use	Yes	County-level fee reductions (varies)	Medical: 1996; Adult-use: 2016
New York	Medical + Adult Use	Yes	Application fee waived for veterans	Medical: 2014; Fee waiver: 2022
Massachusetts	Medical + Adult Use	Yes	Proposed: Self-certification with DD-214, fee waiver	Medical: 2012; Proposed bill: 2026
Illinois	Medical + Adult Use	Yes (added 2019)	PTSD added specifically for veterans	Medical: 2013; PTSD added: 2019
New Mexico	Medical + Adult Use	Yes	Alternative certification with VA records	Medical: 2007; Alt. cert.: 2023
Oklahoma	Medical only	Yes (any condition)	Constitutional language prioritizing veteran access	Medical: 2018
Florida	Medical only	Yes	No specific veteran provisions	Medical: 2016
Pennsylvania	Medical only	Yes	No specific veteran provisions	Medical: 2016
Ohio	Medical + Adult Use (pending)	Yes	Reduced application fee for veterans ($25 vs. $50)	Medical: 2016; Adult-use approved: 2023
Arizona	Medical + Adult Use	Yes	No specific veteran provisions	Medical: 2010; Adult-use: 2020

California

California's medical marijuana program, established by Proposition 215 in 1996, does not require state registration, though the voluntary Medical Marijuana Identification Card Program provides legal protections. PTSD qualifies under the broad "any condition for which marijuana provides relief" standard. Some counties, including Los Angeles and San Diego, offer reduced MMIC fees for veterans, though implementation varies by county. With approximately 1.6 million veterans, California has the largest veteran population of any state. The state's adult-use legalization in 2016 reduced the practical importance of medical certification for many veterans, though medical cardholders receive higher possession limits and tax exemptions.

New York

New York's medical marijuana program added PTSD as a qualifying condition in 2016 following veteran advocacy. In 2022, the state legislature passed a bill eliminating the $50 registration fee for veterans, making New York one of the first states to waive fees specifically for veteran applicants. Veterans must still obtain certification from a registered practitioner, and the state does not accept VA medical records as substitute certification. New York's program requires recertification annually. The state's 2021 adult-use legalization created a parallel system, but medical patients retain advantages including higher possession limits and access to products not available in adult-use dispensaries.

Massachusetts

Massachusetts Governor Maura Healey's September 2026 bill represents the most significant state-level innovation in veterans medical marijuana access. The proposed legislation would allow veterans to obtain medical marijuana cards by presenting DD-214 discharge papers and self-attesting to a qualifying condition, eliminating the physician certification requirement. The bill would waive the state's $50 biennial registration fee for veterans and direct the Cannabis Control Commission to develop veteran-specific educational materials. If enacted, Massachusetts would become the first state to allow medical marijuana access without any physician involvement. The proposal has drawn support from veteran organizations but criticism from medical associations concerned about bypassing clinical evaluation. Massachusetts has approximately 350,000 veterans.

Illinois

Illinois added PTSD as a qualifying condition to its medical marijuana program in 2019, explicitly citing veteran needs in the legislative debate. The state's program requires physician certification but accepts telemedicine consultations, improving access for rural veterans. Illinois does not waive fees for veterans; the state charges $100 for a three-year registration. The state's 2020 adult-use legalization reduced medical program enrollment, but medical patients retain advantages including higher purchase limits (2.5 ounces per 14 days vs. 1 ounce per transaction for adult-use) and lower taxes. Illinois has approximately 630,000 veterans.

New Mexico

New Mexico's 2023 alternative certification pathway allows veterans with PTSD diagnoses documented in VA medical records to obtain medical marijuana cards without a separate physician visit. Veterans must submit VA records showing a PTSD diagnosis code (F43.10 or related ICD-10 codes) along with proof of veteran status. This model recognizes that many veterans already have qualifying diagnoses documented in VA care but cannot get VA physicians to complete state certification forms. The program has enrolled approximately 3,200 veterans since implementation. New Mexico's medical marijuana program predates its 2021 adult-use legalization and remains active with approximately 120,000 registered patients statewide.

Oklahoma

Oklahoma's 2018 State Question 788, which established the state's medical marijuana program, included constitutional language stating that the program should "afford patients and physicians the right to use and recommend medical marijuana." While not creating specific veteran benefits, the program's broad qualifying condition standard (any condition a physician believes would benefit from cannabis) and relatively low barriers to entry have made it accessible to veterans. Oklahoma charges $100 for a two-year patient license with no veteran discount. The state has approximately 310,000 veterans and has issued more than 400,000 medical marijuana licenses, suggesting high per-capita participation.

Florida

Florida's medical marijuana program, established by constitutional amendment in 2016, lists PTSD as a qualifying condition. The state requires physician certification from a doctor who has completed a state-approved cannabis education course and has an established physician-patient relationship. Florida charges $75 annually for medical marijuana cards with no veteran discount. The state's large veteran population (approximately 1.5 million, second only to California) has driven advocacy for veteran-specific accommodations, but legislative efforts to waive fees or create alternative certification pathways have not advanced. Florida does not have adult-use legalization, making medical certification the only legal access pathway.

Pennsylvania

Pennsylvania's medical marijuana program, enacted in 2016, includes PTSD as a qualifying condition. The state requires physician certification and charges $50 annually for patient registration, with no veteran-specific fee waivers. Pennsylvania has approximately 850,000 veterans. The state's program prohibits smokable flower, limiting patients to vaporization, tinctures, topicals, and edibles. This restriction has drawn criticism from veterans who report that inhalation provides faster symptom relief for acute PTSD episodes. Legislative efforts to allow smokable flower have stalled.

Ohio

Ohio's medical marijuana program, launched in 2019, lists PTSD as a qualifying condition and offers a reduced registration fee for veterans ($25 compared to $50 for non-veterans). The state requires physician certification from a doctor who has completed a state certificate-to-recommend course. Ohio voters approved adult-use legalization in November 2023, with sales beginning in 2024, but the medical program remains active with distinct advantages for registered patients. Ohio has approximately 730,000 veterans.

Arizona

Arizona's medical marijuana program, established by voter initiative in 2010, includes PTSD as a qualifying condition. The state charges $150 for an annual medical marijuana card with no veteran discount, though patients receiving Supplemental Security Income qualify for a reduced $75 fee. Arizona's 2020 adult-use legalization reduced the practical importance of medical certification, but medical patients retain higher possession limits (2.5 ounces vs. 1 ounce) and can grow up to 12 plants if they live more than 25 miles from a dispensary. Arizona has approximately 550,000 veterans.

Market and Business Implications

Veterans represent a significant and growing segment of the medical marijuana market, with unique consumption patterns, product preferences, and price sensitivity that influence multi-state operator strategies and product development. The veteran medical marijuana market is estimated at $2.8 billion annually as of 2026, representing approximately 12% of the total U.S. medical cannabis market. This figure includes both registered medical marijuana patients who are veterans and veterans purchasing through adult-use channels for medical purposes. The market has grown at a compound annual rate of 18% since 2020, outpacing overall medical marijuana market growth of 11% over the same period. Multi-state operators have increasingly developed veteran-specific marketing and discount programs. Curaleaf, the largest MSO by revenue, offers a 20% veteran discount at all locations and has partnered with veteran organizations for educational events. Trulieve, dominant in the Florida market with its large veteran population, offers a 15% veteran discount and has sponsored research at the University of Miami on cannabis for PTSD. Green Thumb Industries operates a "Serving Those Who Served" program with discounts and veteran hiring initiatives. Product preferences among veteran consumers differ from general medical marijuana populations. Industry sales data shows veterans purchase higher ratios of tinctures and capsules (32% of veteran purchases vs. 18% overall), reflecting preferences for discrete, dosage-consistent formats. Veterans also show higher interest in CBD-dominant and balanced THC:CBD products compared to recreational consumers who favor high-THC strains. Strains marketed for PTSD and anxiety, including Northern Lights, Granddaddy Purple, and Blue Dream, show disproportionate sales to veteran consumers. Pricing dynamics present challenges. Veterans, particularly those on fixed disability incomes, show high price sensitivity. The average veteran medical marijuana patient spends $180-240 monthly on cannabis products, compared to $280-320 for non-veteran medical patients. This has driven demand for veteran discount programs and has made fee waivers significant for state program participation. In states without veteran discounts, enrollment rates among veterans are 15-20% lower than in states with discount programs, according to data compiled by the National Cannabis Industry Association. The inability of VA physicians to recommend cannabis creates market inefficiencies. Veterans must pay for private physician consultations, typically $100-300, before accessing state programs. This has spawned a cottage industry of cannabis-focused medical practices, some operating on telemedicine platforms, that specialize in rapid certifications. While these services increase access, they often lack the comprehensive medical history available in VA records and may not integrate cannabis recommendations with other medications. Several multi-state operators have acquired or partnered with telemedicine platforms to streamline the certification process for veteran customers. Federal tax policy under Internal Revenue Code Section 280E significantly impacts cannabis business economics. Section 280E prohibits businesses trafficking in Schedule I or II substances from deducting ordinary business expenses, resulting in effective tax rates of 70% or higher for cannabis companies. If the DEA's proposed rescheduling to Schedule III is finalized, 280E would no longer apply, potentially reducing prices by 15-25% according to industry analysts. This would disproportionately benefit price-sensitive veteran consumers. Insurance coverage remains absent for medical marijuana due to federal prohibition. Veterans using VA healthcare for other conditions must pay out-of-pocket for cannabis, creating a bifurcated care model. The average veteran medical marijuana patient spends $2,160-2,880 annually on cannabis products, compared to typical VA prescription copays of $5-11 per 30-day supply. This cost differential limits access for veterans on fixed incomes and may drive some veterans to continue using opioids covered by VA pharmacy benefits. Capital markets have responded to the veteran medical marijuana opportunity. Several cannabis-focused investment funds have emerged with veteran leadership and veteran-market focus. Poseidon Asset Management, founded by former Navy SEAL Morgan Fox, has raised $150 million for cannabis investments with a stated focus on veteran-serving businesses. The veteran angle has proven attractive to institutional investors seeking social impact narratives alongside financial returns. Employment in the cannabis industry has become a significant post-service career path. Industry surveys suggest 8-12% of cannabis industry employees are veterans, well above the 7% veteran representation in the overall workforce. Several MSOs have formal veteran hiring programs, and the American Legion has partnered with cannabis companies on job placement initiatives. This employment dimension adds complexity to the policy debate, as restrictions on veteran cannabis access may conflict with veteran economic opportunity in the industry.

What Experts Say

Medical researchers, veteran advocates, and policy experts offer diverging perspectives on veterans medical marijuana access, with debate centering on evidence quality, federal-state conflicts, and clinical implementation. Dr. Sue Sisley, a psychiatrist and president of the Scottsdale Research Institute, has led the only federally approved clinical trial of whole-plant cannabis for PTSD in veterans. According to her published statements, preliminary results showed statistically significant reductions in PTSD symptom severity in the cannabis group compared to placebo, with the most pronounced effects in the high-CBD strain arm. Dr. Sisley has stated in congressional testimony that the Schedule I status of cannabis created substantial obstacles to research, including a two-year delay in obtaining study material and restrictions on study design. Dr. Marcel Bonn-Miller, an adjunct professor at the University of Pennsylvania Perelman School of Medicine and former VA researcher, has published extensively on cannabis use patterns among veterans. In a 2023 interview with the Journal of the American Medical Association, Dr. Bonn-Miller stated that while observational data suggests many veterans perceive benefits from cannabis use, the lack of large-scale randomized controlled trials prevents definitive conclusions about efficacy. He noted that veterans' high rates of concurrent cannabis use with other psychiatric medications raises concerns about drug interactions that are poorly studied. The American Psychiatric Association has not endorsed medical marijuana for PTSD, stating in a 2019 position statement that "there is insufficient evidence to support cannabis as a treatment for any psychiatric disorder." The organization has called for further research but emphasized that current evidence does not meet standards for clinical practice guidelines. This position has been cited by opponents of expanded veteran access as reason for caution. Dr. Blessing, a researcher at New York University, published a 2015 review in Neurotherapeutics examining preclinical and clinical evidence for cannabinoids in anxiety disorders including PTSD. The review found that CBD demonstrated anxiolytic effects in animal models and small human studies, but noted that most human studies examined social anxiety disorder rather than PTSD specifically. Dr. Blessing concluded that CBD showed promise but that THC's effects were more complex, with potential for both anxiety reduction and anxiety exacerbation depending on dose and individual factors. Nick Etten, a Navy veteran and executive director of the Veterans Cannabis Project, has stated in media interviews that the current system forces veterans to choose between VA healthcare and legal medical marijuana access. According to Etten, the inability of VA doctors to provide recommendations creates a "second-class" status for veterans compared to civilians in medical marijuana states. The Veterans Cannabis Project has advocated for federal legislation allowing VA physician recommendations as an interim step before broader cannabis reform. The American Legion's position, articulated by National Legislative Director Lawrence Montreuil in 2024 congressional testimony, emphasizes veteran autonomy and the physician-patient relationship. According to Montreuil, the Legion's support for medical marijuana access stems from member feedback indicating that cannabis has helped veterans reduce opioid use and improve quality of life. The Legion's position stops short of endorsing cannabis as a proven treatment, instead framing access as a matter of veteran choice and state rights. Dr. Ziva Cooper, director of the UCLA Center for Cannabis and Cannabinoids, has researched cannabis effects on pain and PTSD symptoms. In a 2022 interview with Scientific American, Dr. Cooper noted that while many veterans report benefits from cannabis use, placebo effects are substantial in pain and PTSD treatment, making controlled trials essential. She stated that the VA's prohibition on physician recommendations creates a paradox where veterans can discuss cannabis use with VA doctors but cannot receive guidance on dosing, strain selection, or drug interactions. Smart Approaches to Marijuana has raised concerns about cannabis use in veteran populations with mental health conditions. According to SAM president Kevin Sabet, speaking at a 2023 policy conference, research shows associations between cannabis use and psychotic symptoms in individuals with PTSD. Sabet has argued that expanding veteran access before definitive efficacy trials could expose vulnerable populations to risks, and that FDA-approved cannabinoid medications should be prioritized over whole-plant cannabis.